Synopsis
Recognise neutropenic sepsis from subtle symptoms, administer empirical antibiotics within the emergency window, identify source and resistance risk, and use validated risk assessment for safe ongoing care.
- Any unwell patient receiving or recently receiving systemic anticancer therapy should be assessed for neutropenic sepsis even without fever.
- Profound neutropenia suppresses local inflammatory signs; malaise, rigors, confusion, diarrhoea, mouth pain, line discomfort or hypotension may be the presentation.
- Record ABCDE observations, venous access, lactate, full count, renal and liver function and cultures, but diagnostic sampling must not delay empirical treatment.
- NICE recommends piperacillin with tazobactam as initial intravenous empirical monotherapy unless patient-specific or local microbiological contraindications require another regimen.
- Do not routinely add an aminoglycoside to initial therapy because toxicity outweighs benefit unless a specific microbiological or local indication exists.
- Do not routinely add a glycopeptide solely because a central venous access device is present; add targeted cover for compatible infection or resistant-organism risk.
- Remove or control an infected line, abscess, obstructed urinary tract or other source with the relevant team while antimicrobials continue.
- Use a validated risk tool and experienced clinical assessment after initial treatment, not visual wellness alone, to select inpatient, step-down or outpatient care.
- Persistent or recurrent fever during prolonged profound neutropenia raises invasive fungal disease and requires specialist imaging, biomarkers and mould-active therapy planning.
- Antibiotic review uses cultures, response, neutrophil trajectory, organ function and source; defervescence alone does not answer every duration or discharge question.
Key red flags
Raised lactate, mottling, oliguria or falling pressure requires immediate sepsis resuscitation and critical-care escalation.
Investigation priorities
Confirm neutropenia and accompanying marrow suppression.
Management branches
Recent anticancer treatment accompanies fever or clinically significant sepsis features.
- Use ABCDE, obtain cultures, lactate, count and organ tests, examine likely portals and begin resuscitation without waiting for a documented neutrophil result.
- Give local empirical intravenous antibiotics immediately, using piperacillin with tazobactam monotherapy when NICE criteria and patient microbiology permit.
- Escalate shock, hypoxia, altered consciousness or rising lactate to critical care and pursue source control in parallel with antimicrobial delivery.
Fever persists or recurs during prolonged profound neutropenia despite appropriate antibacterial treatment.
- Repeat focused examination and cultures and obtain early chest CT and fungal biomarkers according to haematology risk and current prophylaxis.
- Discuss mould-active empirical or pre-emptive therapy with infection and haematology specialists, accounting for azole exposure and organ interactions.
- Review lines, abscess, drug fever, viral infection and tumour fever rather than layering indefinite antibiotics without a new hypothesis.
Key medicines
Piperacillin with tazobactamFirst-line agent: NICE recommends piperacillin with tazobactam as initial empirical intravenous beta-lactam monotherapy unless patient-specific or local microbiological factors contraindicate it. Licensed adult febrile-neutropenia regimen with normal renal function: piperacillin 4 g/tazobactam 0.5 g intravenously every 6 hours. Follow the current local neutropenic-sepsis protocol and adjust dose or interval for renal function and the adopted infusion policy.Review immediate beta-lactam allergy, renal function, sodium load, cytopenia and resistant-organism history; a prior non-severe rash requires precise assessment rather than automatic inferior cover.
Alternative empirical regimenMicrobiology selects a local intravenous beta-lactam or combination regimen immediately for severe allergy, resistant colonisation or a source not covered by standard monotherapy.Avoid routine aminoglycoside or glycopeptide exposure without indication; monitor renal, auditory, marrow, QT and drug-interaction risks of the selected agents.